'Boring' Valeant Poised for Q2 Beat
Shares of Valeant Pharmaceuticals (VRX) were falling over 2% on the heels of disappointing second quarter earnings results from rival Teva Pharmaceuticals Industries (TEVA) - Get Report , whose shares are plummeting over 18%.
But RBC Capital analysts Douglas Miehm and Joel Hurren aren't expecting similar fireworks when Valeant reports next week and raised their price target on the pharmaceutical firm.
"We anticipate $2.25B in revenues, $911MM in Adj. EBITDA, and $0.98 in Adj. EPS. We believe this could be the first 'boring' quarter in a while for VRX and anticipate even a slight beat vs. consensus would lead to a positive reaction in the shares. We expect guidance to be updated to reflect closing of the Dendreon sale."
The analysts hiked their price target on Valeant's stock to $21 per share, up from $19 per share, but reiterated their "Sector Perform" rating.
More of What's Trending on TheStreet:
- Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)
- Tesla Will Need to Raise Cash, and Just Revealed How It Might Get It
- Amazon the Next RadioShack?
- Tim Cook on Trump's Claim that Apple Is Building 3 U.S. Factories: 'There's More We Can Do'